COMPARATIVE OUTCOMES OF THREE DIFFERENT ATLG REGIMENS IN ALLO-HSCT FOR PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RETROSPECTIVE STUDY (EBMT 2026) - Feb 7, 2026 - Abstract #P135; Pres time: Mar 22, 2026; 08:30 AM - 06:00 PM; Location: ePoster Area; "baseline variables—including disease status, sex, graft characteristics including CD34⁺, MNC, and CD3⁺ cell doses and letermovir use—were well balanced... In this real-world cohort, ATLG at 20 mg/kg achieved aGVHD prophylaxis comparable to the 25-mg/kg dose across all efficacy and safety endpoints. Only the addition of CD25 monoclonal antibody to ATLG20 was associated with a significantly lower incidence of severe grade III–IV aGVHD, without increased viral reactivation or toxicity."
Retrospective data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Oncology • CD34
|
|
Xiaohong Liu1; Min Xiong2; Deyan Liu2,1; Jian-Ping Zhang2
|